Shares of NewLink Genetics Corp. (NASDAQ:NLNK) fell 5.4% during trading on Wednesday . The stock traded as low as $10.93 and last traded at $11.00, with a volume of 204,399 shares. The stock had previously closed at $11.63.

Several brokerages have commented on NLNK. Robert W. Baird began coverage on shares of NewLink Genetics Corp. in a report on Tuesday, March 22nd. They set an “outperform” rating and a $27.00 target price on the stock. Mizuho dropped their target price on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Stifel Nicolaus dropped their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald restated a “buy” rating and set a $62.00 target price on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Finally, Zacks Investment Research upgraded shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, July 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $23.29.

The stock’s 50 day moving average price is $11.19 and its 200-day moving average price is $18.26. The firm’s market cap is $312.56 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last announced its earnings results on Friday, April 29th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.70) by $0.88. The company earned $4.34 million during the quarter, compared to the consensus estimate of $2.08 million. Analysts predict that NewLink Genetics Corp. will post ($2.83) EPS for the current fiscal year.

A number of hedge funds recently made changes to their positions in the stock. Russell Frank Co boosted its stake in shares of NewLink Genetics Corp. by 57.1% in the fourth quarter. Russell Frank Co now owns 265,422 shares of the company’s stock valued at $9,712,000 after buying an additional 96,512 shares during the last quarter. EQIS Capital Management boosted its stake in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares during the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.